Health & Wellness Blog - Page 74

Ozempic-Like Drugs in India May Drop 50% in Price from March 2026

Semaglutide-based weight-loss drugs like Ozempic and Wegovy are set for a price revolution in India, with generics launching after patent expiry on March 20, 2026, potentially halving costs. Domestic giants like Sun Pharmaceutical and Dr. Reddy's are gearing up to make these GLP-1 therapies more affordable amid rising obesity rates. This shift could transform access to effective treatments for diabetes and weight management.

Shotlee·Feb 26, 2026·5 min read

GLP-1 Medications

Beyond the Scale: GLP-1 Medications' Impact on Body and Mind

Alexis Ioane hesitated before starting tirzepatide, a GLP-1 medication, but two months in, she's shed pounds, gained energy for her kids, and cleared her mind. While GLP-1s like Ozempic and Wegovy promise transformative weight loss, experts caution about mental health effects. Discover the full story on body and mind impacts.

Shotlee·Feb 26, 2026·6 min read

GLP-1 Medications

Zydus Launches Semaglutide in Reusable Pen After Patent Expiry: Prices to Fall

Zydus Lifesciences is set to revolutionize semaglutide access in India with a reusable adjustable pen device after the patent expires on March 20. Brands like SEMAGLYN™, MASHEMA™, and ALTERMET™ promise easier dosing and lower prices around ₹3,500-4,000 per month. This move could expand GLP-1 therapy for Type 2 diabetes and obesity amid rising demand.

Shotlee·Feb 25, 2026·5 min read

Women's Cardiovascular Health

Heart Disease in Women Projected to Rise 34% by 2050, AHA Warns

Without improved prevention, cardiovascular disease rates in U.S. women could climb from 10.7% in 2020 to 14.4% in 2050, warns the American Heart Association. Rising obesity, diabetes, and high blood pressure are key drivers, especially among younger women and underserved groups. Experts call for urgent action on early detection and lifestyle changes.

Shotlee·Feb 25, 2026·7 min read

GLP-1 Research

Acute Sleep Deprivation Delays GLP-1 Peak Response to Breakfast in Healthy Men

New research shows that one night of total sleep deprivation significantly delays the glucagon-like peptide 1 (GLP-1) peak response to breakfast in healthy young men. This finding highlights how sleep loss disrupts key incretin hormones involved in glucose regulation and appetite control. Discover the study's design and what it means for metabolic health.

Shotlee·Feb 25, 2026·6 min read

Peptide Therapy

GLP-1 Drugs May Treat Rare Genetic Obesity, Japanese Study Finds

A new Japanese study reveals that three popular GLP-1 drugs—semaglutide, tirzepatide, and retatrutide—may offer hope for rare genetic obesity linked to MC4R deficiency. In mice models, these drugs led to significant weight loss despite faulty hunger signals. Experts discuss the potential and limitations for human treatment.

Shotlee·Feb 25, 2026·5 min read

GLP-1 Medications

Tirzepatide Activates Brown Fat to Burn Calories, Mouse Study Shows

Tirzepatide doesn't just curb hunger—it may directly rev up fat-burning brown adipose tissue, according to a groundbreaking mouse study. Researchers separated its metabolic effects from simple calorie restriction, uncovering benefits for energy expenditure and blood glucose control. This could pave the way for more effective obesity therapies.

Shotlee·Feb 25, 2026·6 min read

Weight Loss

Luke Combs on Skipping GLP-1s for Weight Loss: 'Not the Short Way'

Grammy-nominated country singer Luke Combs revealed on The New York Times' Popcast why GLP-1 weight loss drugs aren't for him: he wants to 'beat myself' the hard way. Motivated by his wife and kids, Combs embraces the struggle over quick fixes amid lifelong weight battles. His story highlights the personal choice in pursuing metabolic health.

Shotlee·Feb 25, 2026·6 min read

Pharmaceutical Developments

Pfizer's China GLP-1 Deal and BRAFTOVI Oncology Approval

Pfizer is pushing forward on dual fronts: a major $495M deal for Ecnoglutide in China's booming GLP-1 market and full FDA approval for its BRAFTOVI regimen in metastatic colorectal cancer. Clinical data highlights 15.1% placebo-adjusted weight reduction and a 51% drop in mortality risk from the BREAKWATER study. These moves underscore Pfizer's strategy in metabolic and oncology therapeutics.

Shotlee·Feb 25, 2026·5 min read

Latest Articles

Latest Articles

Ozempic-Like Drugs in India May Drop 50% in Price from March 2026

Beyond the Scale: GLP-1 Medications' Impact on Body and Mind

Zydus Launches Semaglutide in Reusable Pen After Patent Expiry: Prices to Fall

Heart Disease in Women Projected to Rise 34% by 2050, AHA Warns

Acute Sleep Deprivation Delays GLP-1 Peak Response to Breakfast in Healthy Men

GLP-1 Drugs May Treat Rare Genetic Obesity, Japanese Study Finds

Tirzepatide Activates Brown Fat to Burn Calories, Mouse Study Shows

Luke Combs on Skipping GLP-1s for Weight Loss: 'Not the Short Way'

Pfizer's China GLP-1 Deal and BRAFTOVI Oncology Approval

Latest Articles

Ozempic-Like Drugs in India May Drop 50% in Price from March 2026

Beyond the Scale: GLP-1 Medications' Impact on Body and Mind

Zydus Launches Semaglutide in Reusable Pen After Patent Expiry: Prices to Fall

Heart Disease in Women Projected to Rise 34% by 2050, AHA Warns

Acute Sleep Deprivation Delays GLP-1 Peak Response to Breakfast in Healthy Men

GLP-1 Drugs May Treat Rare Genetic Obesity, Japanese Study Finds

Tirzepatide Activates Brown Fat to Burn Calories, Mouse Study Shows

Luke Combs on Skipping GLP-1s for Weight Loss: 'Not the Short Way'

Pfizer's China GLP-1 Deal and BRAFTOVI Oncology Approval